Background & objectives: Patients with rheumatic and musculoskeletal diseases (RMDs) may be at an increased risk of SARS-CO-V2 infection as a result of underlying disease, associated comorbidities and use of potentially immunosuppressive treatments. Further, concern exists regarding whether individuals with rheumatic diseases potentially experience more severe COVID-19 and poorer outcomes. This study was undertaken to…
DNA Methylation Profiles May Shed Light on the Evolution of Arthritis in Patients
A study found DNA methylation profiling may predict if a patient will progress from a diagnosis of undifferentiated arthritis to that of rheumatoid arthritis (RA). The findings also suggest a pre-established epigenetic signature exists in patients diagnosed with undifferentiated arthritis that evolves into RA.
ACR Leaders to Meet with Members of Congress at May 12 Capitol Hill Event
The meetings will focus on legislation affecting rheumatology, including bills on graduate medical education and use of copay assistance funds.
Beating the Workforce Shortage: 4 Practices Share Best Practices in ACR Town Hall
At a recent ACR town hall, four rheumatologists shared strategies that have helped them recruit new physicians amid a significant nationwide rheumatology workforce shortage.
Pre-Eclampsia Risk & Rheumatic Disease
Secher et al. evaluated the risk of pre-eclampsia in pregnant patients with RA, axSpA or PsA, assessing the effect of disease activity and disease-modifying anti-rheumatic drugs on this risk.
2 New Clinical Practice Guidelines for JIA Released
Two new ACR Clinical Practice Guidelines provide recommendations on the pharmacologic management of JIA, focusing on treatment of oligoarthritis, temporomandibular arthritis & systemic JIA, as well as nonpharmacologic therapies, medication monitoring, immunizations & imaging.
ARCTIC Rewind: Effects of Half Dose of csDMARDs in Patients with RA in Remission
A study examined the effect of reducing the dose of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) by half in patients with RA in remission, finding the change increased the incidence of flare in 25% of patients.
FDA Approves Risankizumab-rzaa for PsA
Two recent trials demonstrated the safety and efficacy of risankizumab-rzaa for the treatment of adults with active psoriatic arthritis.
Rheum After 5: Dr. David Pisetsky, Storyteller
David S. Pisetsky, MD, PhD, often tells people that science involves reading and writing as much as conducting experiments. No matter what discoveries are made in the lab, if they can’t be communicated well or put into context, he asks, how can they be used to advance the field and benefit patients? The recipient of…
New No-Surprises Rules May Affect Rheumatology Services at Hospitals
This month, we offer an overview of the federal No Surprises Act, which stipulates that healthcare insurers may not surprise patients with out-of-network care bills, instead requiring healthcare providers and insurers to broker price compromises between themselves. The No Surprises Act, enacted on a bipartisan basis in December 2020, protects patients from surprise billing from…
- « Previous Page
- 1
- …
- 111
- 112
- 113
- 114
- 115
- …
- 821
- Next Page »